Order reprints

Apatinib in the treatment of advanced non-small-cell lung cancer: A meta-analysis

Guo-Can Yu Jun Yang Bo Ye Li-Liang Xu Xiao-Yuan Li Guan-Rong Zheng

*Corresponding author: Guan-Rong Zheng zgr8516@163.com

MBE2019,6,7659doi:10.3934/mbe.2019383

Objectives: The purpose of this meta-analysis was to evaluate the efficacy and toxicity profile of apatinib for the treatment of advanced non-small cell lung cancer (NSCLC). Methods: We systematically searched databases for randomized clinical trials published as of November 25, 2017, in which apatinib treatment was compared to placebo or chemotherapy in patients with advanced NSCLC. Two investigators independently assessed the articles and extracted their data. The hazard ratios (HRs) for progression-free survival (PFS), relative risks (RRs) for overall response rates (ORRs), disease control rates (DCRs), and odds ratios (ORs) for main toxicity were analyzed using the RevMan 5.3 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Results: Our analysis included 413 patients from 5 clinical studies. The pooled HR for PFS was 0.32 (95% confidence interval (CI) 0.21–0.48; P < 0.00001). The pooled RRs for ORR and DCR were 2.03 (95% CI 1.36–3.01; P = 0.0005) and 1.66 (95% CI 1.07–2.57; P = 0.02), respectively. The pooled OR for main toxicity was 1.34 (95% CI, 0.57–3.17; P = 0.5). Conclusions: Apatinib was a viable treatment alternative for advanced NSCLC, as it offered a clinically meaningful and statistically significant improvement in PFS, ORR, and DCR. Moreover, therapy with apatinib did not significantly increase toxicity.

Please supply your name and a valid email address you yourself

Fields marked*are required

Article URL   http://www.aimspress.com/MBE/article/4108.html
Article ID   mbe-16-06-383
Editorial Email  
Your Name *
Your Email *
Quantity *

Copyright © AIMS Press All Rights Reserved